Investigating the comparative effect of high-dose intravenous sulbactam ampicillin with and without amikacin nebulizer in the treatment of patients with ventilator-associated pneumonia caused by resistant Acinetobacter bacteria.
Phase 3
- Conditions
- Ventilator-dependent pneumonia due to resistant Acinetobacter.
- Registration Number
- IRCT20240529061949N1
- Lead Sponsor
- Mashhad University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 72
Inclusion Criteria
All patients over 18 years old with ventilator-dependent pneumonia due to resistant Acinetobacter
Exclusion Criteria
Immunocompromised patients and extubated patients
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie sulbactam ampicillin's activity against resistant Acinetobacter in ventilator-associated pneumonia?
How does high-dose intravenous sulbactam ampicillin compare to standard-of-care antibiotics for resistant Acinetobacter ventilator-associated pneumonia?
What biomarkers can identify patients most likely to respond to sulbactam ampicillin with amikacin nebulizer for resistant Acinetobacter pneumonia?
What are the known adverse events associated with high-dose intravenous sulbactam ampicillin and amikacin nebulizer in ICU patients?
How do combination therapies involving sulbactactam and aminoglycosides compare to monotherapy for resistant Acinetobacter ventilator-associated pneumonia?